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The relationship of early recurrence 
of atrial fibrillation and the 3-month 
integrity of the ablation lesion set
Nebojša Mujović1,2, Milan Marinković1, Nebojša Marković1, Vera Vučićević3, Gregory Y. H. Lip4,5, 
T. Jared Bunch6,7 & Tatjana S. Potpara1,2
Early recurrence of atrial fibrillation (ERAF) after catheter-ablation (CA) can be a transient phenomenon 
due to inflammation, or a harbinger of late AF recurrence due to CA lesion (re)conduction. We studied 
the relationship between ERAF and the 3-month CA lesions integrity. Forty one consecutive AF 
patients who underwent a pulmonary vein isolation (PVI), roof line (RL) and mitral isthmus line (MIL) 
CA were enrolled. At 3 months all patients underwent invasive assessment of the lesion set integrity 
irrespective of ERAF. The PVI, RL and MIL ablation was successful in 100.0%, 95.1% and 82.9% patients, 
respectively. At the 3-month remapping, a gap in PVI-lesion(s), RL or MIL was identified in 61.0%, 
31.7% and 36.6% patients, respectively. Patients with (n = 17, 41.5%) compared to those without 
ERAF (n = 24) had a significantly higher rate of any PV-reconnection (88.2% vs. 41.7%), the right 
PV(s)-reconnection (82.5% vs. 29.2%) and the RL gap (52.9% vs. 16.7%), as well as a higher number of 
reconnected right PVI-segments, all p < 0.05. On multivariate analysis, only the number of reconnected 
right PVI-segments was associated with ERAF (OR 4.26, p = 0.004). The ERAF following PVI + RL + MIL 
ablation was significantly related to 3-month PV-reconnections and the presence of RL gaps.
The incidence of early recurrence of atrial fibrillation (ERAF) after AF catheter-ablation (CA) is approximately 
40%1. Sometimes ERAF is only a transient phenomenon attributed to the ablation-related inflammation and/or 
autonomic denervation1–3. Hence, observance of a 3-month “blanking” period is advocated prior to the definite 
CA outcome assessment1–3.
Nevertheless, ERAF is one of the strongest predictors of late recurrence of atrial arrhythmias and can be 
related to conduction gaps in the ablation lesion(s)3–6. Identifying the higher risk sites for gaps may allow upfront 
modification of routine ablation strategies such as increasing energy delivery to improve the likelihood of durable 
lesion at these critical sites in order to reduce the incidence of ERAF and the late arrhythmia recurrence.
To date, the relationship between ERAF and the long-term integrity of an ablation lesion set is underreported. 
Only one study of paroxysmal AF patients has invasively assessed the relationship between the durability of pul-
monary vein isolation (PVI) and ERAF and found that after 4 weeks ERAF was associated with both PV recon-
nection and the number of veins with gaps5.
However, the prognostic significance of ERAF depends on ablation strategy as additional substrate-based 
ablation on top of PVI may further impact degree of inflammation and autonomic disruption and increase the 
proportion of transient ERAF cases that are not associated with late arrhythmia recurrence6. We have recently 
reported on the persistency of the extensive left atrial (LA) lesion set (i.e., PVI combined with the roof line [RL] 
and the mitral isthmus line [MIL]) at the 3-month follow-up invasive electrophysiological study7. In the present 
study we examined the relationship between ERAF and the integrity of the PVI + RL + MIL lesion set created 
during the index CA of AF, as assessed at 3 months in consecutive patients who all underwent the identical index 
CA procedure.
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Methodology
Study design. This prospective study was conducted in the Clinical Center of Serbia. All participants under-
went the two invasive procedures: (1) the index CA of AF, which included a circumferential PVI accompanied 
with the RL and MIL ablation, and (2) the follow-up electrophysiological study after the 3-month “blanking” 
period post index CA, irrespective of arrhythmia outcome, to evaluate the integrity of the index ablation lesions 
and, if necessary, to re-ablate residual conduction gaps. The study protocol was approved by the hospital ethics 
committee (Clinical Center of Serbia, Ethics committee approval #1860/21, 8th October 2015). All participants 
gave written informed consent to undergo both invasive procedures.
Patient selection. Between November 2015 and February 2016 a total of 65 patients underwent CA of AF in 
our center. Of these, 41 consecutive patients underwent their index CA of symptomatic drug-refractory AF, using 
the pre-specified set of ablation lesions (PVI + RL + MIL) and were enrolled in the present study. In our center, 
this lesion set is used in patients with persistent AF and in patients with paroxysmal AF if their AF episodes have 
lasted >48 hours reflecting more complex LA substrate3,8. Patients were excluded from the present study if they 
had a history of previous CA of AF (n = 8), or their ablation consisted of stand-alone PVI (n = 13) or included an 
alternative strategy for substrate modification (n = 3).
The scheduled 3-month invasive follow-up electrophysiological study was performed between March and May 
2016. After the follow-up procedure all participants were clinically followed until July 2017.
All patients were appropriately anti-coagulated for ≥6 weeks before the CA2,3. All anti-arrhythmic drugs 
(AADs) were ceased >5 half-lives prior to CA, except for amiodarone which was discontinued 3 months before 
the procedure.
Index CA. The strategy for CA using the above mentioned set of lesions and the electro-anatomical mapping 
system (EnSite Velocity, St Jude, Minneapolis MN) was described in detail recently7. All invasive procedures 
were performed under a deep sedation with propofol, midazolam and fentanyl. In patients with ongoing AF or 
atrial tachycardia (AT) at the beginning of the procedure sinus rhythm was restored by electrical cardioversion. 
However, before cardioversion, in patients with regular AT or atrial flutter a tachycardia circuit was determined 
by activation and entrainment mapping.
The order of the LA ablation targets during the procedure was as follows: left PVs, right PVs, the RL and the 
MIL. The recovery of conduction across the ablated lesion (PVs, the RL or MIL) recorded during the procedure 
was considered as the acute reconnection and re-ablation was attempted.
PVI. Navigation of the externally irrigated 4-mm tip ablation catheter (Therapy Cool-Flex, St. Jude Medical) 
was achieved by deflectable long sheath (Agilis NxT, St. Jude Medical). PV activity throughout the procedure 
was assessed using a duodecapolar 20 mm diameter circular mapping catheter. PVs were isolated by contin-
uous lesions encircling the ipsilateral PVs, 10–20 mm from the PV ostia7. Each of the encircling lesions was 
divided into the 4 anatomical segments: superior, anterior, inferior and posterior, Fig. 1. The set-up for radiofre-
quency (RF) ablation at the same site was 43 °C, flow-rate 17 ml/min and 30 W for 40–60 sec on the anterior LA 
wall and 25 W for 30–40 sec on the posterior LA wall. Criteria used for PVI diagnosis are reported elsewhere7,9. 
Figure 1. Schematic illustration of the pre-specified ablation lesion set and the distribution of 3-month 
conduction gaps. The encircling PVI lesions were arbitrarily divided in 4 anatomical segments: superior, 
anterior, inferior and posterior. The 3-month conduction gaps in patients with and without ERAF were 
represented with dark blue and red circles, respectively. The absolute number of gaps in each segment was 
given within the circle and size of the circle roughly correlates with the number of local gaps. LAA, left atrial 
appendage; PVI, pulmonary vein isolation; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary 
vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.
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After the ipsilateral PVI, an additional ablation at antral segments was continued, if necessary, to achieve 
“loss-of-pace-capture” (with 10 mA) along the entire PVI line9.
Substrate-based ablation. The RL and MIL was ablated during continues LA appendage pacing from a 
circular mapping catheter7,10,11. Ablation at each site lasted until electrogram amplitude decreases by >80% or 
potential splits, or to maximally 60–120 sec. The MIL ablation started endocardially, but if necessary, proceeded 
within the distal coronary sinus (18–25 W for 40–60 sec). The ablation end-point was a conduction block across 
the line(s) confirmed by standard electrophysiological criteria and is described in detail in our recent report7. 
Ablation of cavo-tricuspid isthmus was performed if typical atrial flutter was documented2,3,7.
Blanking period after the index procedure. The 3-month blanking period was used, as recom-
mended1–3. At discharge, the AAD used before the index CA was reintroduced and the same AAD was used, if 
possible, during the entire blanking period irrespective of arrhythmia recurrence. Afterwards, all AADs were 
withdrawn. In patients who required amiodarone therapy after the index ablation, the drug was suspended 1 
month before the follow-up procedure. Post-procedural follow-up visits with a 12-lead ECG and 24-hour 
Holter-recording were conducted at discharge, at the months 1, 3, and 6, and thereafter every 6 months2,3. Outside 
the follow-up visits, patients were instructed to obtain an ECG in case of symptoms suggestive of arrhythmia 
recurrence. In symptomatic patients, additional unscheduled tests were obtained as needed, including 24-hour, 
48-hour and/or 7-day Holter-monitoring, spiroergometry, event recorder use for two weeks, and/or intra-hospital 
telemetry-monitoring. The “ERAF” was defined as the finding of any atrial tachyarrhythmia (AF, AT or atrial 
flutter) lasting >30 sec during the 3-month blanking period1–4. In case of ERAF, pharmacological or electrical 
cardioversion was performed. Occurrence of these arrhythmias after 3 months post-ablation was considered the 
“late arrhythmia recurrence”1–4.
Follow-up invasive procedure. At the end of the 3-month blanking period all study participants under-
went invasive electrophysiological study using the same protocol and catheter set-up as in the index procedure. 
Residual PV activity was assessed with circular mapping catheter in sinus rhythm while completeness of the lines 
was evaluated by pacing maneuvers7–11. The “3-month conduction gap” refers to any residual conduction across 
the previous lesions (due to late reconnection or due to failed index ablation) whilst the “3-month reconnec-
tion” was defined more specifically as the resumption of conduction (after successful index ablation). The PVI 
segments with reconnection were classified anatomically according to position of the earliest PV potential at the 
circular mapping catheter, see Fig. 1. All identified conduction gaps were re-ablated.
Statistical analysis. Continuous variables with normal and asymmetrical distribution are presented as 
mean (±standard deviation, SD) and median with interquartile range (IQR: 25th–75th percentile), respectively. 
Categorical variables are summarized as percentages. All variables were initially analyzed using univariate logis-
tic regression and those with p < 0.10 were included in multivariate analysis. The ERAF-free survival rates were 
compared using the Kaplan-Meier analysis and the Log-Rank test. Potential relation between the ERAF timing 
and the 3-month lesion(s) integrity was assessed by the receiving operator curve (ROC) analysis. A two-sided 
P-value of <0.05 was considered statistically significant. Analyses were performed using the SPSS 18.0 software.
Data availability. All data generated and/or analyzed during the current study are available from the corre-
sponding author upon reasonable request.
Ethics approval. The study protocol was approved by the hospital ethics committee (Clinical Center of 
Serbia, Ethics committee approval #1860/21, 8th October 2015). All participants gave written informed consent 
to undergo both invasive procedures.
All methods and measurements were performed in accordance with the relevant guidelines and regulations.
Results
Of 41 patients (mean age 59.7 ± 8.3 years), 78.0% were male and 43.9% had persistent AF. Baseline patient char-
acteristics are presented in Table 1.
The index CA. Successful PVI and block across the RL and MIL at the end of the procedure was achieved 
in 41 (100%), 39 (95.1%) and 34 patients (82.9%), respectively (Table 1). An acute PV, RL or MIL reconnection 
during the procedure occurred in 22 of 41 (53.7%), 5 of 39 (12.8%) and 4 of 34 patients (11.8%) with the initially 
successful lesion, respectively. There was no significant difference in the acute reconnection rate for left and right 
PVs (11/41 [26.8%] vs. 15/41 [36.6%], p = 0.477). Cavo-tricuspid isthmus ablation was performed in 5 patients 
(successful in all). Cardiac tamponade developed in 2 patients due to mitral isthmus perforation, which did not 
interfere with completion of the ablation lesion set and was resolved by pericardiocenthesis (n = 1) or urgent 
surgery (n = 1).
ERAF after the index CA. ERAF was documented in 17 of 41 patients (41.6%), mostly in the form of AT 
(n = 11; 64.7%) or AF (n = 5; 29.4%) and rarely as a typical atrial flutter (n = 1; 5.9%). The arrhythmia was par-
oxysmal in 11 and persistent in 6 patients. ERAF was diagnosed mostly by symptom triggered ECG (n = 13) 
or scheduled Holter-monitoring (n = 3), whilst in one symptomatic patient the recurrence was confirmed by 
additional unscheduled 24-h Holter-monitoring. A single ERAF was documented in 9 patients, and recurrent 
ERAF in 8 (mean 10.1 ± 8.9 episodes per patient). The earliest ERAF was recorded in the weeks 1-2, 3-4 or 
5-6 post-ablation in 11 (64.7%), 4 (23.5%) and 2 patients (11.8%), respectively. The distribution of AADs used 
throughout the blanking period was similar among the patients with and without ERAF (Table 2). The AAD 
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was changed (verapamil for amiodarone) only in one patient experiencing ERAF. No significant association was 
found between the time of first ERAF occurrence (in days) and the prevalence of PV reconnections or the gap in 
the RL and/or MIL (Area Under the Curve: 0.867 [95% CI: 0.68–1.00], p = 0.101) at 3 months.
Follow-up electrophysiological study. The 3-month electrophysiological study started during macro- 
reentrant AT in 5 patients: roof flutter (n = 3), right PVI gap-related AT (n = 1) and AT from anterior LA wall 
(n = 1). A gap in the PVI line(s), RL or MIL was recorded in 5, 4 and 2 of these patients, respectively.
Overall, the 3-month endurance of all lesions was confirmed in 9 of 32 patients (28%) with successful index 
ablation of all targeted lesions (i.e., PVs, RL, MIL). The distribution of the segments along the lesion sets exhibit-
ing the 3-month gap in patients with and without ERAF is illustrated in Fig. 1.
The 3-month reconnection of any PVs was identified in 25 of 41 patients (61.0%). No significant difference was 
recorded in the reconnection rate of the left and right PVs (15/41 [36.6%] vs. 21/41 [51.2%], p = 0.266), Table 2. 
However, the number of PVI segments with the reconnection was significantly higher along the right compared 
to the left PVI lesion (30/164 [18.3%] vs. 16/164 [9.8%], p < 0.001). All reconnected PVs were re-isolated.
The 3-month gap in the RL was observed in 13 of 41 patients (31.7%), due to late reconnection (n = 11) or 
failed index ablation (n = 2). The RL re-ablation led to block in 10 of 13 patients. Late conduction gap in the MIL 
Total
(n = 41)
ERAF
(n = 17)
No ERAF
(n = 24) Univariate p
Baseline clinical data
Age (years) 59.7 ± 8.3 62.2 ± 7.1 57.8 ± 8.8 0.102
Male gender 32 (78.0%) 14 (82.4%) 18 (75.0%) 0.577
BMI (kg/m2) 28.5 ± 4.6 28.8 ± 4.7 28.3 ± 4.6 0.709
Years since AF diagnosis 5.0 (2.0–10.0) 7.0 (5.0–12.0) 3.5 (1.0–8.0) 0.065
Non-paroxysmal AF 18 (43.9%) 7 (41.2%) 11 (45.8%) 0.767
LV EDD (cm) 53.1 ± 4.7 53.7 ± 4.6 52.7 ± 4.8 0.509
LV EF (%) 60.0(55.0–65.0)
60.0
(55.0–65.0)
60.0
(55.0–65.0) 0.936
LA dimension (cm) 43.0 ± 5.7 45.0 ± 5.5 41.5 ± 5.5 0.064
CHA2DS2-VASc score 2.0 (1.0–3.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0) 0.260
Coronary disease 3 (7.3%) 1 (5.9%) 2 (8.3%) 0.768
Cardiomyopathy 5 (12.2%) 2 (11.8%) 3 (12.5%) 0.943
Diabetes 6 (14.6%) 3 (17.6%) 3 (12.5%) 0.647
Hypertension 24 (58.5%) 12 (70.6%) 12 (50.0%) 0.192
CVA 1 (2.4%) 1 (5.9%) 0 (0.0%) —
Failed AADs 2.0 (1.5–2.5) 2.0 (2.0–2.5) 2.0 (1.0–2.5) 0.511
The index CA
Left PVI line (cm) 11.5 ± 2.1 11.8 ± 1.5 11.2 ± 2.5 0.534
Right PVI line (cm) 12.0 ± 1.8 12.5 ± 1.9 11.7 ± 1.6 0.166
Roof line (cm) 3.0 ± 0.7 3.0 ± 0.7 2.9 ± 0.7 0.815
Mitral isthmus line (cm) 3.6 (3.1–4.0) 3.4 (2.9–3.9) 3.7 (3.2–4.0) 0.317
Procedure time (min) 223.4 ± 46.7 239.1 ± 52.2 212.3 ± 39.8 0.078
RF time (min) 74.1 ± 21.7 84.3 ± 26.4 66.8 ± 14.1 0.024
RF deliveries 52.0(45.0–67.0)
62.0
(52.0–71.0)
50.0
(44.0–58.5) 0.054
Fluoroscopy (min) 30.8 ± 9.5 31.7 ± 9.1 30.2 ± 9.9 0.627
PV isolation 41 (100.0%) 17 (100.0%) 24 (100.0%) —
Isolation of the Left PVs “in pair” 27 (65.9%) 10 (58.8%) 17 (70.8%) 0.426
Isolation of the Right PVs “in pair” 13 (31.7%) 4 (23.5%) 9 (37.5%) 0.347
Roof line block 39 (95.1%) 16 (94.1%) 23 (95.8%) 0.803
Mitral isthmus block 34 (82.9%) 15 (88.2%) 19 (79.2%) 0.453
Acute PV(s) reconnection 22 (53.7%) 10 (58.8%) 12 (50.0%) 0.577
Left PV(s) acute reconnection 11 (26.8%) 7 (41.1%) 4 (16.7%) 0.216
Right PV(s) acute 15 (36.6%) 5 (29.4%) 10 (41.7%) 0.330
PVs with acute reconnection (n) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.5 (0.0–1.0) 0.397
Typical AFL ablation 5 (12.2%) 2 (11.8%) 3 (12.5%) 0.943
Table 1. Baseline clinical characteristics of the patients and the index ablation data. Data are presented as 
mean ± standard deviation, median (25th to 75th percentile) or numbers (percentages). ERAF, early recurrence 
of atrial fibrillation; BMI, body mass index; AF, atrial fibrillation; LV, left ventricle; EDD, end-diastolic 
dimension; EF, ejection fraction; LA, left atrium; CVA, cerebro-vascular accident; AAD, anti-arrhythmic drug; 
CA, catheter-ablation; PVI, pulmonary vein isolation; RF, radiofrequency; AFL, atrial flutter.
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was found in 15 of 41 patients (36.6%), due to 3-month reconnection (n = 8) or incomplete index ablation (n = 7). 
After re-ablation, the MIL block was accomplished in 11 of 15 patients.
Freedom from ERAF after the index CA procedure was significantly better among patients with than among 
those without the 3-month integrity of the right PVI lesion (p = 0.002) and the RL (p = 0.022), Fig. 2.
Risk factors for ERAF. Univariate analysis showed that patients with ERAF had significantly longer RF abla-
tion times (p = 0.024) and more reconnections of any PVs (88.2% vs. 41.7%, p = 0.006). Reconnection of the right 
PVs (82.5% vs. 29.2%, p = 0.002) but not the left PVs (47.1% vs. 29.2%, p = 0.245) at 3 months was significantly 
higher in those with ERAF compared to without, respectively (Tables 1 and 2, Figs 3,4 and 5). Also, ERAF patients 
more frequently had a gap in the RL (52.9% vs. 16.7%, p = 0.018) and higher median number of PVs (2.0 [IQR: 
1.0–4.0] vs. 0.0 [0.0–2.0], p = 0.007) and right PVI segments (1.0 [1.0–2.0] vs. 0.0 [0.0–1.0], p = 0.002) showing 
the reconnection. The 3-month gap prevalence in the MIL was similar in patients with and without ERAF (35.3% 
vs. 37.5%, p = 0.885). No significant difference was identified in the circulatory biomarkers of injury at 24 hours 
after the index CA, between patients with and without ERAF. Patients with recurrent ERAF episodes and those 
with single ERAF had similar mean number of reconnected PVs as well as the 3-month gap prevalence in the RL 
or the MIL (all p > 0.05).
All variables shown by univariate analysis to be significantly associated with ERAF (RF ablation time, recon-
nection of any PV, reconnection of the right PVs, a gap in the RL, the number of PVs with reconnection, and the 
number of right PVI segments with reconnection; all p < 0.05) were entered into a multivariate model. However, 
multivariate analysis identified a significant association only between the number of right PVI segments exhibit-
ing 3-month reconnection and the ERAF occurrence (OR 4.26 [95% CI: 1.57–11.52], p = 0.004).
Clinical outcome. The arrhythmia outcome is presented in Fig. 6. After the index ablation, ERAF was 
detected in only 2 of 16 patients (12.5%) with all PVs isolated at 3 months and afterwards these patients were 
arrhythmia-free off-AADs during the further study course. Majority of patients with ERAF (15 of 17, 88.2%) 
exhibited 3-month PV reconnection and underwent re-ablation. After the repeated ablation, ERAF was recorded 
in 4 patients (AT in all). Of these, 3 patients already suffered from ERAF following the index CA procedure. 
During the median follow-up of 18 months (IQR: 16–19 months) after the last performed CA, the late arrhythmia 
Total
(n = 41)
ERAF
(n = 17)
No ERAF
(n = 24) Univariate p
AADs at discharge after the index CA
Propafenone 21 (51.2%) 9 (52.9%) 12 (50.0%) 0.853
Amiodarone 8 (19.5%) 4 (23.5%) 4 (16.7%) 0.586
Sotalol 8 (19.5%) 3 (17.6%) 5 (20.8%) 0.800
Beta-blockers 3 (7.3%) 0 (0%) 3 (12.5%) 0.999
Verapamil 1 (2.4%) 1 (5.9%) 0 (0%) >0.999
Inflammatory markers after the index CA
Leukocytes (n, 109/l) 9.0(7.4–10.7)
8.0
(6.9–10.8)
9.0
(8.0–10.5) 0.843
Neutrophiles (n, 109/l) 6.0 (5.0–8.0) 6.0 (4.9–7.8) 6.0 (5.3–8.5) 0.886
ESR (mm/h) 12.0(8.0–22.0)
10.0
(6.0–16.0)
13.0
(10.0–26.0) 0.074
Fibrinogen (g/l) 3.5 ± 0.9 3.3 ± 1.0 3.7 ± 0.9 0.249
CRP (mg/l) 12.1(7.4–19.0)
12.6
(8.0–22.0)
11.5
(6.6–16.0) 0.222
Troponin I (ng/l) 6.0 (5.0–9.0) 5.0 (3.6–9.5) 6.5 (6.0–9.0) 0.719
CK-MB (u/l) 19.0(16.5–23.5)
19.0
(15.0–22.0)
21.0
(18.0–25.0) 0.287
3-month Follow-up EP procedure
PV reconnection 25 (61.0%) 15 (88.2%) 10 (41.7%) 0.006
Left PVs reconnection 15 (36.6%) 8 (47.1%) 7 (29.2%) 0.245
Right PVs reconnection 21 (51.2%) 14 (82.4%) 7 (29.2%) 0.002
PVs with late reconnection (n) 1.0 (0.0–2.0) 2.0 (1.0–4.0) 0.0 (0.0–2.0) 0.007
Left PVI segments with reconnection (n) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.170
Right PVI segments with reconnection (n) 1.0 (0.0–1.0) 1.0 (1.0–2.0) 0.0 (0.0–1.0) 0.002
Gap in the Roof line 13 (31.7%) 9 (52.9%) 4 (16.7%) 0.018
Gap in the Mitral isthmus line 15 (36.6%) 6 (35.3%) 9 (37.5%) 0.885
Table 2. Data after the index ablation and from the 3-month electrophysiology procedure. Data are 
presented as mean ± standard deviation, median (25th to 75th percentile) or numbers (percentages). ERAF, 
early recurrence of atrial fibrillation; AAD, anti-arrhythmic drug; CA, catheter-ablation; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; CK-MB, creatin-kinase MB iso-enzyme; EP, electrophysiology; PV, 
pulmonary vein; PVI, pulmonary vein isolation.
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recurrence was documented in total of 3 patients (AT in all), all of which experienced ERAF after the 3-month 
ablation procedure. At last follow-up, 38 of 41 patients (92.7%) were arrhythmia-free.
Discussion
In our study of 41 consecutive AF patients who underwent the uniform set of RF ablation lesions (PVI + RL + MIL) 
and the follow-up invasive 3-month electrophysiological study, the ERAF occurrence was significantly related to 
reconnection of the ablation lesions, and not the biomarkers of injury, thus suggesting that the 3-month “blank-
ing” period might not be justified in paroxysmal/persistent AF patients with ERAF post-ablation comprising PVI 
with additional linear and substrate ablation. However our study was not powered to identify the ERAF patients 
who would benefit from early re-ablation.
Figure 2. Kaplan-Meier curves of freedom from ERAF during the blanking period after the index ablation in 
patients grouped by 3-month integrity of the left PVI lesion (A), the right PVI lesion (B), the Roof line (C) and 
the Mitral isthmus line (D).ERAF, early recurrence of atrial fibrillation; PVI, pulmonary vein isolation.
Figure 3. The prevalence (A) and the extensiveness (B) of PV reconnection at 3 months among patients with 
and those without ERAF. PV, pulmonary vein; ERAF, early recurrence of atrial fibrillation.
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The 3-month ERAF incidence under AAD therapy was 41.2% in our study. In this setting, the 3-month 
follow-up invasive assessment showed a signficiant association with right PVs reconnection and conduction gaps 
in the RL among patients with ERAF. The timing and repetitiveness of ERAF was not related to the long-term 
integrity of the ablation lesion set.
Clinical significance of ERAF. The reported incidence of ERAF varies considerably, between 16% and 67%, 
with a pooled estimate of 37.8%1. The rate of ERAF is the highest in the first two weeks after CA and then progres-
sively declines1–3,12. Our study confirmed these findings.
In some patients, the ERAF is only a temporary event due to the LA inflammation, gradually subsiding over 
the next weeks1–3,12. However as evidenced in this study, the ERAF can be related to the recovery of conduc-
tion across the ablation lesion(s) from the index ablation and recent clinical studies identified ERAF as one 
Figure 4. The prevalence (A,B) and the extensiveness (C,D) of the 3-month conduction recovery across the left 
and the right PVI lesions, respectively, in patients categorized based on the ERAF occurrence. PV, pulmonary 
vein; PVI, pulmonary vein isolation; ERAF, early recurrence of atrial fibrillation.
Figure 5. The prevalence of 3-month conduction gap in the Roof line (A) and the Mitral isthmus line (B) in 
relation to the ERAF history during the blanking period. ERAF, early recurrence of atrial fibrillation.
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of the strongest predictors for the late arrhythmia recurrence2–5. Currently, data on the relationship between 
ERAF and the long-term integrity of ablation lesions are mostly limited to patients with clinically overt late 
arrhythmia relapse which prompted repeat invasive study2–4. Only one study of patients with paroxysmal AF 
reported on the association between the ERAF and durability of PVI5. In our study, probably due to the LA linear 
ablation, two-thirds of ERAFs were organized ATs and not AF. Recurrent ATs after AF ablation are commonly 
persistent (and not paroxysmal); compared with AF, post-procedural ATs are more commonly associated with 
hemodynamic deterioration (e.g., heart failure, syncope) due to fast ventricular response and refractoriness to 
rate-controlling drugs, AADs and cardioversions, thus often requiring subsequent multiple ablation procedures13.
ERAF and the durability of PVI. In the recent study, a protocol mandated invasive remapping 2 months 
post-PVI showed that the ERAF limited to the first month post-procedure was not related to the late PV recon-
nection while the ERAF occurring or continuing beyond the first month was strongly associated with more exten-
sive (>1 PV) reconnection5. Recent clinical studies supported these findings and demonstrated that the delayed 
occurrence of ERAF within the 3-month blanking period significantly increased the risk for the late arrhythmia 
recurrence; nonetheless controversies regarding mechanisms and significance persist14,15.
In our study, ERAF was related to the presence as well as the extent of PV reconnection at the 3-month inva-
sive electrophysiological study, without a temporal relationship between the ERAF occurrence and the PVI integ-
rity. Discrepancy between our results and the previous findings could be explained by non-uniform follow-up 
strategies throughout the blanking period, potentially influencing the ERAF expression and detection5. In the 
previously mentioned study, AAD use was limited to 1 month post-ablation while our patients continued taking 
AADs for 3 months5. In addition, the methods for ERAF screening were different (a handheld ECG-monitoring 
device vs. 24-hour Holter-monitor). Nevertheless, the ERAF rates in both studies were very similar (17/40 vs. 
17/41)5. Finally, our study included a discrete ablation strategy that comprised PVI with additional linear ablation 
that likely influenced temporal healing as well as patients with persistent AF.
In the study by Das et al., no discernible relationship between the reconnected PV(s) (i.e., left PVs or right 
PVs) and the ERAF occurrence was observed5. Although the 3-month reconnection rates of the left and right PVs 
were similar in our study, we found a significantly more reconnections along the right PVI line (vs. left PVI line), 
mostly across its anterior and posterior segments, correlating with the local atrial wall thickness16,17. Although 
rates of reconnection along the left PVI lines were higher in the ERAF group, the difference was not significant. 
Figure 6. Flow-chart diagram of the clinical course after the index ablation and the 3-month invasive 
evaluation (with re-ablation). EP, electrophysiology; PAF, paroxysmal atrial fibrillation, Pe-AF, persistent 
atrial fibrillation; PV, pulmonary vein; RL, roof line; MIL, mitral isthmus line; ERAF, early recurrence of atrial 
fibrillation; PAT, paroxysmal atrial tachycardia; Pe-AT, persistent atrial tachycardia; LRAF, late recurrence of 
atrial fibrillation; FU, follow-up.
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In addition, a higher number of the right PVI segments with reconnection were observed in those with ERAF 
compared to those without. Therefore, we speculate that the clinically overt ERAF requires the reconnection of 
a critical number of fibers at the level of PV-LA junction. Presently, it is not known if a more durable right PVs 
isolation will positively impact ERAF expression and long-term outcomes.
The following findings of our study merit consideration: first, at the 3-month follow-up study we identified 
the PV reconnection in almost all patients experiencing ERAF (15 of 17, 88.2%). Since the 3-month procedure 
included a mandatory re-ablation of the gaps, the long-term clinical significance of these ERAF cases remained 
unclear. However, according to these findings, probably all patients with ERAF, irrespective to its timing, deserve 
intense monitoring in the further post-procedural course until the final decision on repeat CA procedure is made. 
Second, 2 of 16 patients with durable PVI at 3 months had ERAF during the blanking period and afterwards were 
arrhythmia-free. This finding confirmed that ERAF can be provoked by transient pro-arrhythmic factors oper-
ating immediately post-ablation such as inflammation, but the incidence of these “purely temporal” ERAF cases 
was considerably lower (12.5%) than in the other studies (30–50%)1–3,14,15. These findings underline the notion 
that PVI integrity is one of the most important prerequisites for long-term AF ablation success and highlights 
the necessity for additional technological and procedural improvements in order to provide a more durable PVI.
ERAF and the integrity of the Roof line. To the best of our knowledge, we were the first to report the 
relationship between ERAF and the long-term completeness of the LA lines in a population of patients with 
paroxysmal and persistent AF. It has been shown that an extensive substrate-based RF ablation (beyond PVI) 
increased the proportion of patients with transient ERAF due to acute reversible electrophysiological alterations 
after the procedure1,6,12. Contrary to other reports1–3,12,18, the levels of biomarkers of inflammation and myo-
cardial necrosis obtained 24 h after CA procedure in our study were similar in patients with and without ERAF, 
although RF delivery time was significantly longer in those with ERAF probably reflecting the difficulties in 
reaching the endpoint(s). We showed that incompleteness of the RL (but not MIL) at 3 months was strongly 
associated with ERAF. The role of the LA roof in the mechanisms of AF has been previously described10,19,20. The 
achievement of RL block resulted in cycle length prolongation, termination and non-inducibility of paroxysmal 
AF and interruption of the LA reactivation circuits in persistent AF10,19. The relative importance of integrity of 
the RL compared to MIL for ERAF occurrence in our report may be explained by the different distribution of the 
low-voltage areas reflective of arrhythmogenic substrate at the roof (49%) compared to the mitral isthmus (6%) 
in AF patients20. The adjuvant substrate modification based on these low-voltage areas ablation (beyond PVI) 
significantly improved the long-term outcome in both patients with persistent and paroxysmal AF20. Therefore, 
we assume that despite the (re)activation of the triggers post-ablation (due to LA inflammation and/or late PV 
reconnections), the presence of an intact RL block after the index ablation might preclude the perpetuation of 
clinically detectable ERAF episodes.
Study limitations. This was a single centre study with a limited number of participants due to the ethical 
issues of exposing the arrhythmia-free patients to a repeated invasive procedure. The follow-up invasive study 
included the gap(s) reablation, thus precluding the assessment of long-term clinical significance of ERAF in these 
patients. However, avoidance of closing the conduction gaps during the redo procedure would have been ethically 
problematic.
The intermittent rhythm monitoring during the post-ablation follow-up (i.e., 24-hour Holter-monitoring) 
could affect the ERAF detection12 but our strategy was in line with usual clinical practice and current guidelines1–3.
We did not use the contact-force catheters that may have potentially compromised the PVI durability. 
However, the late PV reconnection rate of 62% after contact-force guided PVI in a recent report5 as well as the 
3-month reconnection distribution and extensiveness along the right PVI line (vs. left PVI line) after PVI per-
formed with contact-force guidance in other studies17,21 were similar to our findings.
Conclusions
In the present study systematically evaluating the relation between ERAF and the index ablation lesion integrity, 
the incidence of ERAF was 41% during the 3-month follow-up and in most patients ERAF occurred during the 
first month post-ablation. At the 3-month invasive remapping, patients with ERAF more frequently exhibited any 
PVs reconnection, right PVs reconnection and a gap in the RL, as well as a more extensive PV reconnection in 
terms of the higher number of the PVs segments recovering the conduction compared with non-ERAF patients. 
Our findings question the validity of the “blanking” period approach to determine procedural success in patients 
that undergo PVI and linear ablation and the assumption that ERAF consistently reflects reversible mechanisms 
of arrhythmia.
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